MT Newswires
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
📊
AI Sentiment
Positive
6/10
- Home
- BCYC
as of 12-12-2025 3:58pm EST
$7.50
+$0.07
+0.94%
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
Chart Type:
Time Range:
| Founded: | 2009 | Country: | United Kingdom |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 438.4M | IPO Year: | 2019 |
| Target Price: | $18.73 | AVG Volume (30 days): | 303.3K |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.03 - $21.21 | Next Earning Date: | 10-30-2025 |
| Revenue: | $28,339,000 | Revenue Growth: | -23.20% |
| Revenue Growth (this year): | -7.54% | Revenue Growth (next year): | -5.32% |
AI-Powered BCYC Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 73.83%
73.83%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Bicycle Therapeutics plc (BCYC)
Skynner Michael
Sell
CHIEF TECHNOLOGY OFFICER
BCYC Oct 3, 2025
Avg Cost/Share
$8.41
Shares
978
Total Value
$8,224.98
Owned After
118,277
SEC Form 4
Hannay Michael Charles Ferguson
Sell
CHIEF PROD & SUPPLY CHAIN OFF
BCYC Oct 3, 2025
Avg Cost/Share
$8.41
Shares
250
Total Value
$2,102.50
Owned After
53,102
SEC Form 4
Thompson Travis Alvin
Sell
CHIEF ACCOUNTING OFFICER
BCYC Oct 3, 2025
Avg Cost/Share
$8.41
Shares
103
Total Value
$866.23
Owned After
31,197
SEC Form 4
Milnes Alistair
Sell
CHIEF OPERATING OFFICER
BCYC Oct 3, 2025
Avg Cost/Share
$8.41
Shares
978
Total Value
$8,224.98
Owned After
93,377
SEC Form 4
Skynner Michael
Sell
CHIEF TECHNOLOGY OFFICER
BCYC Oct 2, 2025
Avg Cost/Share
$8.40
Shares
824
Total Value
$6,921.60
Owned After
118,277
SEC Form 4
Hannay Michael Charles Ferguson
Sell
CHIEF PROD & SUPPLY CHAIN OFF
BCYC Oct 2, 2025
Avg Cost/Share
$8.40
Shares
473
Total Value
$3,973.20
Owned After
53,102
SEC Form 4
Thompson Travis Alvin
Sell
CHIEF ACCOUNTING OFFICER
BCYC Oct 2, 2025
Avg Cost/Share
$8.40
Shares
221
Total Value
$1,856.40
Owned After
31,197
SEC Form 4
Young Alethia
Sell
Chief Financial Officer
BCYC Oct 2, 2025
Avg Cost/Share
$8.50
Shares
482
Total Value
$4,103.13
Owned After
44,704
Milnes Alistair
Sell
CHIEF OPERATING OFFICER
BCYC Oct 2, 2025
Avg Cost/Share
$8.40
Shares
1,147
Total Value
$9,634.80
Owned After
93,377
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Skynner Michael | BCYC | CHIEF TECHNOLOGY OFFICER | Oct 3, 2025 | Sell | $8.41 | 978 | $8,224.98 | 118,277 | |
| Hannay Michael Charles Ferguson | BCYC | CHIEF PROD & SUPPLY CHAIN OFF | Oct 3, 2025 | Sell | $8.41 | 250 | $2,102.50 | 53,102 | |
| Thompson Travis Alvin | BCYC | CHIEF ACCOUNTING OFFICER | Oct 3, 2025 | Sell | $8.41 | 103 | $866.23 | 31,197 | |
| Milnes Alistair | BCYC | CHIEF OPERATING OFFICER | Oct 3, 2025 | Sell | $8.41 | 978 | $8,224.98 | 93,377 | |
| Lee Kevin | BCYC | CHIEF EXECUTIVE OFFICER | Oct 3, 2025 | Sell | $8.41 | 3,231 | $27,172.71 | 475,310 | |
| Skynner Michael | BCYC | CHIEF TECHNOLOGY OFFICER | Oct 2, 2025 | Sell | $8.40 | 824 | $6,921.60 | 118,277 | |
| Hannay Michael Charles Ferguson | BCYC | CHIEF PROD & SUPPLY CHAIN OFF | Oct 2, 2025 | Sell | $8.40 | 473 | $3,973.20 | 53,102 | |
| Thompson Travis Alvin | BCYC | CHIEF ACCOUNTING OFFICER | Oct 2, 2025 | Sell | $8.40 | 221 | $1,856.40 | 31,197 | |
| Young Alethia | BCYC | Chief Financial Officer | Oct 2, 2025 | Sell | $8.50 | 482 | $4,103.13 | 44,704 | |
| Milnes Alistair | BCYC | CHIEF OPERATING OFFICER | Oct 2, 2025 | Sell | $8.40 | 1,147 | $9,634.80 | 93,377 |
Latest Bicycle Therapeutics plc News
BCYC Breaking Stock News: Dive into BCYC Ticker-Specific Updates for Smart Investing
MT Newswires
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading
📊
AI Sentiment
Positive
6/10
MT Newswires
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
âž–
AI Sentiment
Neutral
5/10
Compare BCYC vs Leading Stocks
See how BCYC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BCYC Bicycle Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.